Sanofi Enters Multi-Billion Dollar Antibody Deals with Adagene and IGM

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)

Published: 31 Mar-2022

DOI: 10.3833/pdr.v2022.i3.2681     ISSN: 1756-7874

Section: Licensing



Sanofi has been particularly busy on the deal making front in March 2022, entering into a number of key collaboration and licensing agreements in an attempt to bolster its therapeutic antibody pipeline...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details